BACKGROUND: Pediatric patients admitted for acute lung disease are treated and monitored in the hospital, after which full recovery is achieved at home. Many studies report in-hospital recovery, but little is known regarding the time to full recovery after hospital discharge. Technological innovations have led to increased interest in home-monitoring and digital biomarkers. The aim of this study was to describe at-home recovery of 3 common pediatric respiratory diseases using a questionnaire and wearable device. METHODS: In this study, patients admitted due to pneumonia (n = 30), preschool wheezing (n = 30), and asthma exacerbation (AE; n = 11) were included. Patients were monitored with a smartwatch and a questionnaire during admission, with a 14-day recovery period and a 10-day "healthy" period. Median compliance was calculated, and a mixed-effects model was fitted for physical activity and heart rate (HR) to describe the recovery period, and the physical activity recovery trajectory was correlated to respiratory symptom scores. RESULTS: Median compliance was 47% (interquartile range [IQR] 33-81%) during the entire study period, 68% (IQR 54-91%) during the recovery period, and 28% (IQR 0-74%) during the healthy period. Patients with pneumonia reached normal physical activity 12 days postdischarge, while subjects with wheezing and AE reached this level after 5 and 6 days, respectively. Estimated mean physical activity was closely correlated with the estimated mean symptom score. HR measured by the smartwatch showed a similar recovery trajectory for subjects with wheezing and asthma, but not for subjects with pneumonia. CONCLUSIONS: The digital biomarkers, physical activity, and HR obtained via smartwatch show promise for quantifying postdischarge recovery in a noninvasive manner, which can be useful in pediatric clinical trials and clinical care.
BACKGROUND: Pediatric patients admitted for acute lung disease are treated and monitored in the hospital, after which full recovery is achieved at home. Many studies report in-hospital recovery, but little is known regarding the time to full recovery after hospital discharge. Technological innovations have led to increased interest in home-monitoring and digital biomarkers. The aim of this study was to describe at-home recovery of 3 common pediatric respiratory diseases using a questionnaire and wearable device. METHODS: In this study, patients admitted due to pneumonia (n = 30), preschool wheezing (n = 30), and asthma exacerbation (AE; n = 11) were included. Patients were monitored with a smartwatch and a questionnaire during admission, with a 14-day recovery period and a 10-day "healthy" period. Median compliance was calculated, and a mixed-effects model was fitted for physical activity and heart rate (HR) to describe the recovery period, and the physical activity recovery trajectory was correlated to respiratory symptom scores. RESULTS: Median compliance was 47% (interquartile range [IQR] 33-81%) during the entire study period, 68% (IQR 54-91%) during the recovery period, and 28% (IQR 0-74%) during the healthy period. Patients with pneumonia reached normal physical activity 12 days postdischarge, while subjects with wheezing and AE reached this level after 5 and 6 days, respectively. Estimated mean physical activity was closely correlated with the estimated mean symptom score. HR measured by the smartwatch showed a similar recovery trajectory for subjects with wheezing and asthma, but not for subjects with pneumonia. CONCLUSIONS: The digital biomarkers, physical activity, and HR obtained via smartwatch show promise for quantifying postdischarge recovery in a noninvasive manner, which can be useful in pediatric clinical trials and clinical care.
Authors: Johannes H Wildhaber; Josué Sznitman; Paul Harpes; Daniel Straub; Alexander Möller; Pavel Basek; Felix H Sennhauser Journal: Respir Care Date: 2007-12 Impact factor: 2.258
Authors: Michael Harris; Julia Clark; Nicky Coote; Penny Fletcher; Anthony Harnden; Michael McKean; Anne Thomson Journal: Thorax Date: 2011-10 Impact factor: 9.139
Authors: M D Kruizinga; F E Stuurman; V Exadaktylos; R J Doll; D T Stephenson; G J Groeneveld; G J A Driessen; A F Cohen Journal: Pharmacol Rev Date: 2020-10 Impact factor: 25.468
Authors: Piush J Mandhane; Patricia Paredes Zambrano de Silbernagel; Yin Nwe Aung; Janie Williamson; Bonita E Lee; Sheldon Spier; Mary Noseworthy; William R Craig; David W Johnson Journal: PLoS One Date: 2017-08-03 Impact factor: 3.240
Authors: Matthijs D Kruizinga; Esmée Essers; F E Stuurman; Ahnjili Zhuparris; Nellie van Eik; Hettie M Janssens; Iris Groothuis; Arwen J Sprij; Marianne Nuijsink; Adam F Cohen; Gertjan J A Driessen Journal: Pediatr Pulmonol Date: 2020-07-08
Authors: Stephen Joel Coons; Sonya Eremenco; J Jason Lundy; Paul O'Donohoe; Hannah O'Gorman; William Malizia Journal: Patient Date: 2015-08 Impact factor: 3.883
Authors: Rachel G Greenberg; Amy Corneli; John Bradley; John Farley; Hasan S Jafri; Li Lin; Sumathi Nambiar; Gary J Noel; Chris Wheeler; Rosemary Tiernan; P Brian Smith; Jamie Roberts; Daniel K Benjamin Journal: Contemp Clin Trials Commun Date: 2017-11-26